Cytek Biosciences, Inc. (CTKB) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cytek Biosciences, Inc. (CTKB) Healthcare & Pipeline Overview

Cytek Biosciences, Inc. delivers cell analysis solutions, including full spectrum flow cytometers and reagents, serving pharmaceutical, biopharma, and academic research sectors. Their Aurora and Northern Lights systems offer advanced cell analysis by utilizing fluorescence signatures, positioning them in the competitive medical devices market.

What Is the Investment Thesis for CTKB?

Cytek Biosciences operates in the growing cell analysis market, driven by increasing demand for advanced biomedical research tools. The company's full spectrum flow cytometry technology offers a competitive advantage, enabling more detailed cell analysis compared to traditional methods. While Cytek's gross margin stands at 51.7%, its profit margin is -36.2%, indicating potential challenges in achieving profitability. Key growth catalysts include expanding the installed base of Aurora and Northern Lights systems and increasing reagent sales. The company's beta of 1.28 suggests higher volatility compared to the overall market. Investors should monitor the company's ability to improve profitability and capitalize on growth opportunities in the cell analysis market.

Based on FMP financials and quantitative analysis

CTKB Key Highlights

Market capitalization of $602M reflects investor valuation of Cytek's future growth potential.

• Gross margin of 51.7% indicates strong pricing power and efficient cost management in product manufacturing.
• Negative profit margin of -36.2% highlights the need for improved operational efficiency and cost control.
• Beta of 1.28 suggests higher volatility compared to the market, potentially offering higher returns but also greater risk.
• Cytek's focus on full spectrum flow cytometry positions it in a high-growth segment of the cell analysis market.

Who Are CTKB's Competitors?

CTKB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CTKB's Key Strengths?

Proprietary full spectrum flow cytometry technology.

• Strong brand recognition in the cell analysis market.
• Established customer base.
• Innovative product portfolio.

What Are CTKB's Weaknesses?

Negative profit margin.

• High operating expenses.
• Limited market share compared to larger competitors.
• Dependence on research and development for new products.

What Could Drive CTKB Stock Higher?

Expansion of the installed base of Aurora and Northern Lights systems.

• Increasing sales of reagents and kits.
• Penetration of the clinical market.
• Geographic expansion in emerging markets.
• Development of new applications for flow cytometry.

What Are the Key Risks for CTKB?

Negative return on equity (-20.8%) — the business is not currently generating profit on shareholder capital.

• Intense competition from established players.
• Technological advancements by competitors.
• Changes in regulatory requirements.
• Economic downturn affecting research funding.
• Negative profit margin.

What Are the Growth Opportunities for CTKB?

• Expansion of Reagent Sales: Cytek can drive growth by increasing the sales of its cFluor reagents and other kits. As the installed base of Aurora and Northern Lights systems grows, the demand for compatible reagents will also increase. The global reagents market for flow cytometry is estimated to be worth billions of dollars, offering a substantial opportunity for Cytek to expand its revenue stream. Timeline: Ongoing.
• Penetration of Clinical Market: Cytek has the opportunity to expand its presence in the clinical market by offering its cell analysis solutions for diagnostic and monitoring applications. The increasing adoption of flow cytometry in clinical settings, such as hematology and immunology, presents a significant growth opportunity. Timeline: Ongoing.
• Geographic Expansion: Cytek can pursue growth by expanding its sales and distribution network in emerging markets, particularly in Asia-Pacific and Latin America. These regions are experiencing rapid growth in biomedical research and healthcare spending, creating a favorable environment for Cytek's products. Timeline: Ongoing.
• Development of New Applications: Cytek can invest in research and development to expand the applications of its full spectrum flow cytometry technology. This includes exploring new areas such as drug discovery, immunotherapy, and cell therapy. The development of new applications will broaden Cytek's addressable market and drive revenue growth. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: Cytek can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. This includes partnering with companies that offer complementary technologies or acquiring companies that have a strong presence in specific geographic markets. Strategic collaborations can accelerate Cytek's growth and enhance its competitive position. Timeline: Ongoing.

What Are CTKB's Competitive Advantages?

• Proprietary full spectrum flow cytometry technology.
• Strong brand recognition in the cell analysis market.
• Established customer base in pharmaceutical, biopharma, and academic research sectors.
• Extensive sales and distribution network.

What Does CTKB Do?

Cytek Biosciences, Inc., founded in 1992 and headquartered in Fremont, California, is a cell analysis solutions company focused on advancing biomedical research and clinical applications. Originally named Cytoville, Inc., the company rebranded as Cytek Biosciences, Inc. in August 2015. Cytek develops, manufactures, and markets a range of cell analysis tools, including its flagship Aurora and Northern Lights systems, which are full spectrum flow cytometers. These systems utilize fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells, enabling comprehensive cell analysis. The company's product portfolio also includes the Aurora cell sorter system, reagents and kits like cFluor reagents (fluorochrome conjugated antibodies), and a 25-color immunoprofiling assay for identifying major human immune subpopulations. Additionally, Cytek offers automated micro-sampling and sample loader systems, SpectroFlo software for data analysis, and customer support tools. Cytek serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales and support teams in North America, Europe, China, and the Asia-Pacific region, as well as through distributors and sales agents in other global markets.

What Products and Services Does CTKB Offer?

• Develops and manufactures full spectrum flow cytometers.
• Offers Aurora and Northern Lights systems for advanced cell analysis.
• Provides reagents and kits, including cFluor reagents.
• Offers automated micro-sampling and sample loader systems.
• Develops SpectroFlo software for data analysis.
• Provides customer support tools and services.
• Serves pharmaceutical, biopharma, academic research centers, and clinical research organizations.

How Does CTKB Make Money?

• Sells cell analysis instruments (Aurora, Northern Lights, Aurora cell sorter).
• Generates recurring revenue through the sale of reagents and kits.
• Provides software and service contracts for installed instruments.
• Distributes products through direct sales and distributors.

What Industry Does CTKB Operate In?

Cytek Biosciences operates within the medical devices industry, specifically in the cell analysis segment. This segment is driven by advancements in biomedical research, increasing demand for personalized medicine, and the growing adoption of flow cytometry techniques. The market is competitive, with established players and emerging companies offering various cell analysis solutions. Cytek's full spectrum flow cytometry technology differentiates it from traditional flow cytometry methods, offering higher resolution and more comprehensive data.

Who Are CTKB's Key Customers?

• Pharmaceutical companies
• Biopharmaceutical companies
• Academic research centers
• Clinical research organizations

Wall Street analysts project Cytek Biosciences, Inc. revenue of about $209.1M for fiscal 2026, with EPS near $-0.34. The estimate reflects 3 contributing analysts.

Cytek Biosciences, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 190.2% below estimates on average.

Cytek Biosciences, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.44 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Cytek Biosciences, Inc. stands at -20.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.4%, the inverse of the P/E and a quick read on earnings relative to price.

Cytek Biosciences, Inc. (CTKB) Valuation Context

Valued at $602M, CTKB is classified as a small-cap stock. Relative to its peer group, CTKB's quantitative score of 28/100 is below the peer average of 71/100.

CTKB Revenue & Earnings Trend

In Q2 2026, CTKB generated $48.1M in top-line revenue, marking a sequential increase of 9.1%. The company recorded a net loss of $12.2M, with diluted EPS of $-0.09. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CTKB averaged $-0.16 in diluted EPS.

Company Profile

Cytek Biosciences, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Fremont, US. The company is led by CEO Wenbin Jiang. CTKB has traded publicly since 2021.

CTKB Financials

CTKB Latest News

CTKB Analyst Consensus

CTKB MoonshotScore

Common Questions About CTKB (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources